WO2005041920A3 - Pharmaceutical licofelone formulation - Google Patents
Pharmaceutical licofelone formulation Download PDFInfo
- Publication number
- WO2005041920A3 WO2005041920A3 PCT/EP2004/012266 EP2004012266W WO2005041920A3 WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3 EP 2004012266 W EP2004012266 W EP 2004012266W WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- licofelone
- formulation
- water soluble
- copolymers
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a solid pharmaceutical formulation containing licofelone or a physiologically acceptable salt thereof and at least one water soluble polymer selected from the group containing hydroxyalkyle celluloses, methyl cellulose, polyvinyl pyrrolidones and copolymers thereof, polyvinyl alcohols, saponified or partially saponified copolymers of N-vinyl pyrrolidone and vinyl esters, and/or at least one water soluble polyol selected from polyethylene glycols having a molecular weight in the region of 8.000 - 20.000 and sugar alcohols. The invention also relates to a formulation which releases the active ingredient in a rapid manner.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10351035.4 | 2003-10-31 | ||
DE10351035A DE10351035A1 (en) | 2003-10-31 | 2003-10-31 | Pharmaceutical Licofelone formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005041920A2 WO2005041920A2 (en) | 2005-05-12 |
WO2005041920A3 true WO2005041920A3 (en) | 2005-07-14 |
Family
ID=34485181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/012266 WO2005041920A2 (en) | 2003-10-31 | 2004-10-29 | Pharmaceutical licofelone formulation |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR046205A1 (en) |
DE (1) | DE10351035A1 (en) |
TW (1) | TW200524592A (en) |
WO (1) | WO2005041920A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109718220A (en) * | 2017-10-27 | 2019-05-07 | 天津药物研究院有限公司 | The preparation method of ML-4000 clathrate capsule |
EP3593792A1 (en) | 2018-07-11 | 2020-01-15 | Welding GmbH & Co. KG | Pharmaceutical composition comprising 6- (4-chlorophenyl) -2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid cholin salt |
WO2023089636A1 (en) * | 2021-11-21 | 2023-05-25 | Aizant Drug Research Solutions Private Limited | Pharmaceutical compositions of licofelone |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041626A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
US20020143033A1 (en) * | 1996-02-13 | 2002-10-03 | G.D. Searle & Co. | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
WO2002089791A2 (en) * | 2001-04-30 | 2002-11-14 | Zouboulis Christos C | Acne treatment with lipooxigenase inhibitors |
WO2003097041A1 (en) * | 2002-05-17 | 2003-11-27 | Merckle Gmbh | Annelated pyrrole compounds as proton pump inhibitors for treating ulcer |
-
2003
- 2003-10-31 DE DE10351035A patent/DE10351035A1/en not_active Withdrawn
-
2004
- 2004-10-27 AR ARP040103905A patent/AR046205A1/en unknown
- 2004-10-29 WO PCT/EP2004/012266 patent/WO2005041920A2/en active Application Filing
- 2004-10-29 TW TW093133050A patent/TW200524592A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996041626A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
US6136839A (en) * | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
US20020143033A1 (en) * | 1996-02-13 | 2002-10-03 | G.D. Searle & Co. | Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
WO2002089791A2 (en) * | 2001-04-30 | 2002-11-14 | Zouboulis Christos C | Acne treatment with lipooxigenase inhibitors |
WO2003097041A1 (en) * | 2002-05-17 | 2003-11-27 | Merckle Gmbh | Annelated pyrrole compounds as proton pump inhibitors for treating ulcer |
Also Published As
Publication number | Publication date |
---|---|
DE10351035A1 (en) | 2005-05-25 |
TW200524592A (en) | 2005-08-01 |
AR046205A1 (en) | 2005-11-30 |
WO2005041920A2 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002051385A8 (en) | Solid dispersions of nitrate active principles | |
ES2486848T3 (en) | Confectionery Product | |
UA94917C2 (en) | Topical formulations | |
WO2007071581A3 (en) | Pharmaceutical formulation for producing rapidly disintegrating tablets | |
EP1649851A3 (en) | Pregelatinized starch in a controlled release formulation | |
CA2331264A1 (en) | Compositions and methods for drug delivery | |
WO2000041681A3 (en) | MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST | |
CA2312710A1 (en) | Sustained release formulation containing three different types of polymers and tablet formed therefrom | |
IL149573A0 (en) | Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients | |
WO2004010998A8 (en) | Sustained-release tablet comprising reboxetine | |
MXPA03008886A (en) | Polyhydroxyalkanoate copolymer and polylactic acid polymer compositions for laminates and films. | |
EP2716284A3 (en) | Polyethylene oxide-based films and drug delivery systems made herefrom | |
WO2005025499A3 (en) | Hydrophobic drug compositions containing reconstitution enhancer | |
WO2001060335A3 (en) | Delivery systems using preformed biodegradable polymer compositions and methods | |
WO2007068615A3 (en) | Hcv prodrug formulation | |
WO2006059029A3 (en) | Solutions viscoelastiques renfermant du hyaluronate de sodium et de l ' hydroxypropylmethylcellulose | |
WO2008148742A3 (en) | Pharmaceutical formulation for the production of rapidly disintegrating tablets | |
WO2003000777A3 (en) | Multi-arm block copolymers as drug delivery vehicles | |
CA2566931A1 (en) | Tablets exhibiting reduced drug release variability | |
MY130332A (en) | Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer | |
CA2346868A1 (en) | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent | |
WO2003059382A3 (en) | Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression | |
AU2697100A (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
WO2004100883A3 (en) | Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same | |
WO2005041920A3 (en) | Pharmaceutical licofelone formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |